Oak Point Wealth Management bought a new stake in Johnson & Johnson (NYSE:JNJ) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 3,324 shares of the company’s stock, valued at approximately $469,000.
A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Harding Loevner LP purchased a new stake in Johnson & Johnson in the 2nd quarter worth approximately $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. boosted its position in Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares in the last quarter. Mountain Capital Investment Advisors Inc purchased a new stake in Johnson & Johnson in the 2nd quarter worth approximately $124,000. Lenox Wealth Management Inc. boosted its position in Johnson & Johnson by 1.7% in the 2nd quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after purchasing an additional 24 shares in the last quarter. Finally, Intercontinental Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth approximately $200,000. Hedge funds and other institutional investors own 67.21% of the company’s stock.
In related news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.19% of the stock is currently owned by corporate insiders.
JNJ stock opened at $131.21 on Wednesday. Johnson & Johnson has a 52 week low of $120.95 and a 52 week high of $148.32. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $349,421.19, a price-to-earnings ratio of 17.84, a P/E/G ratio of 2.07 and a beta of 0.77.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a return on equity of 29.00% and a net margin of 1.70%. The firm had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. During the same period in the prior year, the company earned $1.58 EPS. The firm’s revenue was up 11.5% compared to the same quarter last year. equities analysts predict that Johnson & Johnson will post 8.11 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th were paid a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.56%. The ex-dividend date was Monday, February 26th. Johnson & Johnson’s dividend payout ratio is currently 861.54%.
Several equities research analysts have commented on the company. JPMorgan Chase & Co. lowered Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price objective on the stock in a research report on Wednesday, December 20th. BMO Capital Markets upped their price objective on Johnson & Johnson to $161.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 12th. Jefferies Group set a $165.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Monday, February 26th. Finally, BTIG Research reiterated a “sell” rating and set a $110.00 target price on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $146.26.
COPYRIGHT VIOLATION WARNING: “Oak Point Wealth Management Invests $469,000 in Johnson & Johnson (JNJ) Stock” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this story can be read at https://ledgergazette.com/2018/03/21/oak-point-wealth-management-invests-469000-in-johnson-johnson-jnj-stock.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.